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Abstract 
Introduction: The rearrangement of the anaplastic lymphoma kinase (ALK) gene accounts for approximately 1%–6% 
of lung adenocarcinoma cases and defines a molecular subgroup of tumors characterized by clinical sensitivity to ALK 
inhibitors such as crizotinib. This study aimed to identify the relationship between ALK rearrangement and the clinico‑
pathologic characteristics of non‑small cell lung cancer (NSCLC) and to analyze the therapeutic responses of crizotinib 
and conventional chemotherapy to ALK rearrangement in NSCLC patients.
Methods: A total of 487 lung cancer patients who underwent testing for ALK rearrangement in our department were 
included in this study. ALK rearrangement was examined by using fluorescence in situ hybridization (FISH) assay.
Results: Among the 487 patients, 44 (9.0%) were diagnosed with ALK rearrangement by using FISH assay. In 123 
patients with adenocarcinoma who were non‑smokers and of a young age (≤58 years old), the frequency of ALK 
rearrangement was 20.3% (25/123). Short overall survival (OS) was associated with non‑adenocarcinoma tumor type 
(P = 0.006), poorly differentiated tumors (P = 0.001), advanced‑stage tumors (P < 0.001), smoking history (P = 0.008), 
and wild‑type epidermal growth factor receptor (EGFR) (P = 0.008). Moreover, patients with poorly differentiated 
and advanced‑stage tumors had a shorter time to cancer progression compared with those with well differentiated 
(P = 0.023) and early‑stage tumors (P = 0.001), respectively.
Conclusions: ALK‑rearranged NSCLC tends to occur in younger individuals who are either non‑smokers or light 
smokers with adenocarcinoma. Patients with ALK rearrangement might benefit from ALK inhibitor therapy.
Keywords: Anaplastic lymphoma kinase rearrangement, Non‑small cell lung cancer, Fluorescence in situ 
hybridization, Pathology
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Background
Lung cancer is a lethal but common disease with a 5-year 
survival rate of approximately 5%–15% [1]. Molecu-
lar targeted therapy is emerging as an effective thera-
peutic strategy for many cancers [2–4]. The following 
molecularly targeted genes are potentially relevant to 
oncogenic events and have demonstrated remarkable 
significance: the v-raf murine sarcoma viral oncogene 
homolog B1 (BRAF), human epidermal growth factor 
receptor-2 (HER2), phosphoinositide 3′-kinase (PI3K), 
v-Ki-ras 2 Kirsten rat sarcoma viral oncogene homolog 
(KRAS), discoidin domain receptor 2 (DDR2), epidermal 
growth factor receptor (EGFR), anaplastic lymphoma 
kinase (ALK), c-ros oncogene 1 (ROS1), and ret proto-
oncogene (RET). ALK rearrangement represents a new 
oncogene driver [5, 6].
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The echinoderm microtubule-associated protein like 4 
(EML4)-ALK in non-small cell lung cancer (NSCLC) was 
first discovered as an oncogenic driver gene in 2007; the 
EML4-ALK fusion gene was generated by an inversion 
in the short arm of chromosome 2 [6]. According to the 
breakpoint on EML4 (from exon 2 to exon 20), 13 vari-
ants of the EML4-ALK fusion gene have been found [7]. 
Recently, the TRK-fused gene (TFG), the kinesin family 
member 5B (KIF5B), and the kinesin light chain 1 (KLC1) 
were reported to invert and fuse to ALK in NSCLC [5, 8, 
9].
Compared with other genetic abnormalities in NSCLC, 
the frequency of the ALK rearrangement is approximately 
1%–6% in unselected NSCLC [10–12]. Patients with ALK 
rearrangement are highly sensitive to crizotinib, an oral 
tyrosine kinase inhibitor (TKI) of the c-Met proto-onco-
gene (c-Met), ALK, and ROS1 genes. The powerful and 
specific therapeutic efficacy of this drug on ALK-rear-
ranged NSCLC led to the approval by the Food and Drug 
Administration (FDA) in the United States [13]. Several 
studies have shown that most of the patients who har-
bor this chromosomal abnormality have benefited from 
targeted therapy. A randomized phase III study reported 
that, in the subgroup of ALK-rearranged NSCLC, patients 
treated with crizotinib showed higher response rate and 
longer progression-free survival (PFS) compared with 
those treated with the standard second-line chemothera-
pies (docetaxel or pemetrexed) [14]. Other studies showed 
dramatic clinical benefits associated with crizotinib in 
patients with ALK-rearranged NSCLC [15, 16].
The tumors from patients with ALK rearrangements 
are characterized by distinct histologic features including 
a solid or acinar growth pattern, a cribriform structure, 
the presence of mucous cells and abundant extracellular 
mucus, a lack of lepidic growth, and nuclear pleomor-
phism [17]. Nevertheless, these histologic parameters 
are of insufficient sensitivity and specificity to detect 
ALK rearrangements, and therefore, histomorphology 
should not replace confirmatory molecular or immu-
nohistochemical studies [17]. The histomorphology of 
ALK-rearranged lung cancer cannot be used as a screen-
ing method. Several methods including reverse transcrip-
tion-polymerase chain reaction (RT-PCR), fluorescence 
in  situ hybridization (FISH), and immunohistochemis-
try (IHC) are currently used to identify ALK transloca-
tions in patients with NSCLC. In the present study, we 
performed ALK FISH in NSCLC cases at the Sun Yat-
sen University Cancer Center (SYSUCC) using the gold 
standard method, Abbott ALK break-apart probe. We 
analyzed the clinicopathologic features of the patients, 
their survival status, and the relationship between the 
clinicopathologic features and ALK rearrangement. In 
previous studies, ALK rearrangement represented a 
unique molecular subset of NSCLC with no overlap with 
cancers that featured alterations in the EGFR or KRAS 
genes [18, 19]. According to EGFR and ALK status, we 
retrospectively studied the responses of patients to tradi-
tional therapies compared with targeted therapies.
Patients and methods
Patient selection
We reviewed 1,000 patients with NSCLC who were 
observed and tested for ALK rearrangement at the Depart-
ment of Molecular Diagnostics of SYSUCC between Feb-
ruary 2012 and November 2013. Patients were involved 
into this study based on the following criteria: complete 
clinical data, complete follow-up information, and suffi-
cient paraffin tissue from primary tumors at the time of the 
initial genetic diagnosis. The patients were excluded if they 
received any treatment outside of SYSUCC or had a pre-
vious history of other cancers that were identified either 
before or after the NSCLC. Finally, a total of 487 patients 
were enrolled in this study. All cases were confirmed 
independently by two experienced pathologists. Patho-
logic staging was defined according to the International 
Association for the Study of Lung Cancer (IASLC) TNM 
staging classification of NSCLC [20]. Histopathologic clas-
sification of the cancers was determined according to the 
2004 World Health Organization (WHO) histological clas-
sification of lung cancer [21]. Patients were classified as 
non-smokers if they smoked for less than 10 pack-years 
or smokers if they smoked for 10 pack-years or more in 
their lifetime. This study was approved by the Institutional 
Research Medical Ethics Committee of SYSUCC.
FISH assay
Formalin-fixed, paraffin-embedded, 4-μm sections were 
used for FISH detection. According to the hematoxylin 
and eosin stain of the same tissue block, the tumor por-
tion on each slide was selected and demarcated by a sin-
gle pathologist. The FISH assay included the use of the 
Vysis LSI ALK Dual Color, Break Apart Probe (Abbott 
Molecular Inc. Des Plaines, IL, USA), which hybridizes to 
the 2p23 band with 3′-ALK spectrum orange and 5′-ALK 
spectrum green. The slides were deparaffinized prior to 
probe application. Detailed FISH staining procedures 
have been previously described [22].
FISH signals for each locus-specific FISH probe were 
assessed under an Olympus BX51 TRF microscope (Olym-
pus, Tokyo, Japan) equipped with a triple-pass filter (DAPI/
Green/Orange; Abbott Molecular Inc. Des Plaines, IL, 
USA). Any tissues with questionable tumor areas were 
reviewed and noted by a pathologist; the FISH results were 
evaluated by two independent and experienced patholo-
gists. Cases with ALK rearrangements were determined 
to exhibit one of two patterns: the first type was a classic 
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pattern with one fusion signal (native ALK) and two sepa-
rated orange and green signals; the other was an atypical 
pattern with one fusion signal (native ALK) and an isolated 
orange signal. By using the signal size as a reference, the 
tumor cells were considered positive when the probe sepa-
ration distance in ALK-rearranged tumors was larger than 
the two signal diameters in normal tissue [23]. When ALK 
break-apart signals were found in more than 15% of no less 
than 50 counted tumor cells, the tumor samples were con-
sidered ALK rearrangement-positive [23–25]. The tumor 
samples with a single green signal or an increased copy 
number of non-rearranged ALK genes with fused signals 
that corresponded to polysomy of chromosome 2 or ALK 
amplification were considered ALK rearrangement-negative 
[23]. For each case, the entire slide was reviewed for possible 
areas where rearrangements might have been missed.
EGFR mutation
DNA was extracted by a DNA FFPE tissue kit (Qiagen, 
Valencia, CA, USA) according to the manufacturer’s 
instructions. DNA was quantified by a NanoDrop 2000 
Spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA), and a total of 200 ng DNA was used for PCR. 
Nucleotide sequencing of the kinase domain of EGFR 
(exons 18, 19, 20, and 21) was performed with PCR 
amplification and Sanger sequencing. PCR-amplified 
products were purified with a PCR purification kit (Qia-
gen, Valencia, CA, USA) and were sequenced with a Big-
Dye Terminator Cycle Sequencing Reaction Kit and an 
ABI 3500 XL Genetic Analyzer (Hitachi, Tokyo, Japan).
Follow‑up and classification of cause of death
The clinical data including follow-up information were 
obtained from the medical record system as well as by 
telephone interview. The collection of follow-up data for 
each case was executed based on a semi-annual schedule. 
For deceased patients, we classified the underlying cause 
of death as stated on the death certificate. Local relapse 
was defined as recurrence of lung cancer as determined by 
biopsy, whereas distant metastasis was defined according 
to evidence shown on a chest computed tomography (CT) 
scan, abdominal ultrasound, or bone scan. The overall sur-
vival (OS) was defined as the period from the date of diag-
nosis to death from any cause or the date of last contact; 
the PFS was defined as the period from the date of diag-
nosis to the first regional or distant metastasis. The last 
follow-up was performed in April 2014, and the median 
follow-up was 18.8 months (range 0.3–172.2 months). In 
total, 86 (17.7%) cases died during follow-up.
Statistical analysis
The relationship between ALK status and the clinicopatho-
logic features was analyzed by using Chi square test and 
Fisher’s exact test. Kaplan–Meier curves with the log-rank 
test were applied for OS and PFS analysis. Cox propor-
tional hazards models were used to compare independent 
predictive factors of each biological and clinicopathologic 
feature. A two-sided statistical significance was defined as 
P < 0.05. All analyses were performed with SPSS 16.0 Sta-
tistics software (SPSS Inc., Chicago, IL, USA).
Results
Clinicopathologic characteristics
Of the 487 patients, 133 (27.3%) underwent biopsies, and 
354 (72.7%) underwent surgical resections. Briefly, 303 
(62.2%) were males, and 184 (37.8%) were females, with 
a median age of 58 years (range 25–86 years). The histo-
logical types included adenocarcinomas (78.4%, 382/487) 
and non-adenocarcinomas (21.6%, 105/487); the 105 
non-adenocarcinomas comprised 73 squamous carcino-
mas, 25 large cell carcinomas, and 7 sarcomatoid carci-
nomas. The clinicopathologic characteristics of the 487 
patients with lung cancer are listed in Table 1.
Table 1 Associations between ALK rearrangement and the 
clinicopathologic characteristics of 487 patients with non-
small cell lung cancer (NSCLC)
ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor.








Total 487 443 (91.0) 44 (9.0)
Age
 ≤58 years 261 (53.6) 229 (51.7) 32 (72.7) 0.008
 >58 years 226 (46.4) 214 (48.3) 12 (27.3)
Sex
 Male 303 (62.2) 279 (63.0) 24 (54.5) 0.271
 Female 184 (37.8) 164 (37.0) 20 (45.5)
Histological type
 Adenocarcinoma 382 (78.4) 339 (76.5) 43 (97.7) 0.001
 Others 105 (21.6) 104 (23.5) 1 (2.3)
Differentiation
 Well 206 (42.3) 187 (42.2) 19 (43.2) 0.901
 Poor 281 (57.7) 256 (57.8) 25 (56.8)
Clinical stage
 I + II 226 (46.4) 213 (48.1) 13 (29.5) 0.019
 III + IV 261 (53.6) 230 (51.9) 31 (70.5)
Smoking history
 Non‑smoker 239 (49.1) 207 (46.7) 32 (72.7) 0.001
 Smoker 248 (50.9) 236 (53.3) 12 (27.3)
EGFR mutation status
 Negative 328 (67.4) 285 (64.3) 43 (97.7) <0.001
 Positive 159 (32.6) 158 (35.7) 1 (2.3)
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Detection of ALK rearrangement by FISH
Of the 487 NSCLC cases, 44 (9.0%) were identified with 
ALK rearrangements. The percentage of ALK break-apart 
signals ranged from 16% to 90%. Of the 44 ALK-rear-
ranged cases, 15 (34.1%) showed more than 50% split flu-
orescence signals, and 29 (65.9%) demonstrated less than 
50% split signals. The mean percentage of positive nuclei 
was 51.7% in the cases with ALK rearrangement. Among 
the 44 patients with ALK rearrangement, the median age 
was 49 years (range 25–80 years). We compared the clin-
icopathologic characteristics between the ALK-fusion-
positive group and the ALK-fusion-negative group and 
found significant differences in age (P = 0.008), histologi-
cal type (P =  0.001), clinical stage (P =  0.019), smoking 
history (P = 0.001), and EGFR mutation status (P < 0.001); 
no significant difference was found in other clinicopatho-
logic parameters between the two groups (Table 1).
Of the 44 patients with ALK rearrangement, 43 (97.7%) 
had adenocarcinomas, and 1 (2.3%) had squamous car-
cinoma (Fig. 1). Of the 43 cases of adenocarcinomas, 30 
(69.8%) were typical adenocarcinomas, 6 (14.0%) were 
mucinous adenocarcinomas, and 3 (7.0%) were papillary 
adenocarcinomas. Intriguingly, we found 4 ALK-rear-
ranged adenocarcinomas with morphologic features of 
focal squamous differentiation. The predominant compo-
nents of typical adenocarcinomas were as follows: acinar 
growth pattern in 25 cases, solid growth pattern in two 
cases, and mixed growth pattern in three cases.
Analysis of EGFR mutation status and clinical 
characteristics in patients with NSCLC
Of the 487 patients, we identified 159 (32.6%) with EGFR 
mutations in exons 18, 19, 20, and 21. Of the 159 cases, 
68 (42.8%) were determined to have an exon 19 deletion, 
3 (1.9%) had an exon 20 mutation, and 87 (54.7%) had an 
exon 21 mutation. We found that 1 (0.6%) case exhibited 
double mutations (15 bp deletion and L858R). However, 
no mutations were detected in exon 18. The predominant 
types of mutations were found in exons 19 and 21, which 
accounted for 97.5% of the mutations. Significant differ-
ences were shown in age (P = 0.030), sex (P < 0.001), his-
tological type (P < 0.001), differentiation (P < 0.001), and 
Fig. 1 Representatives of hematoxylin–eosin (H&E) staining and fluorescence in situ hybridization (FISH) in non–small cell lung cancer (NSCLC) 
lesions with anaplastic lymphoma kinase (ALK) rearrangement. a An ALK‑rearranged adenocarcinoma with a mucinous pattern by H&E staining 
(×200). b An ALK‑rearranged squamous carcinoma with a solid growth pattern by H&E staining (×200). c ALK break‑apart signals by FISH with a split 
orange (staining 3′‑2 chromosomal/DNA region) and green (staining 5′‑2 chromosomal/DNA region) signal pattern (red arrows), indicating an ALK 
rearrangement‑positive status. d ALK break‑apart signals by FISH with an isolated orange signal pattern (yellow arrows), indicating an ALK rearrange‑
ment‑negative status.
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smoking history (P < 0.001) between the EGFR mutation-
negative group and the EGFR mutation-positive group. 
However, no significant difference was observed in other 
clinical characteristics (Table 2).
Survival analysis of NSCLC patients
Using the Kaplan–Meier estimate method, we found 
that the OS was significantly associated with histologi-
cal type (P  =  0.006), differentiation (P  =  0.001), clini-
cal stage (P  <  0.001), smoking history (P  =  0.008), and 
EGFR mutation status (P  =  0.008) (Fig.  2). However, 
the OS showed no significant association with age 
(P  =  0.794), sex (P  =  0.144), or ALK rearrangement 
status (P  =  0.300) (data not shown). On the contrary, 
patients with poorly differentiated tumors and those with 
advanced-stage tumors had a shorter time to cancer pro-
gression compared with those with well differentiated 
tumors (P  =  0.023) and those with early-stage tumors 
(P = 0.001) (Fig. 3). The PFS showed no significant asso-
ciation with age (P = 0.293), sex (P = 0.958), histological 
type (P = 0.099), smoking history (P = 0.442), ALK rear-
rangement status (P =  0.212), or EGFR mutation status 
(P = 0.464) (data not shown).
Several variables including age, sex, histological type, 
differentiation, clinical stage, smoking history, tumor 
status, lymph node status, metastasis status, EGFR muta-
tion status, and ALK rearrangement status were analyzed 
by using univariate and multivariate Cox proportional 
hazard regression analyses. The univariate analysis results 
showed that the OS significantly associated with his-
tological type [hazard ratio (HR) 1.971, 95% confidence 
interval (CI) 1.200–3.235, P = 0.007], differentiation (HR 
0.449, 95% CI 0.279–0.721, P = 0.001), clinical stage (HR 
3.091, 95% CI 1.855–5.149, P  <  0.001), smoking history 
(HR 1.779, 95% CI 1.153–2.747, P =  0.009), T category 
(HR 2.475, 95% CI 1.605–3.816, P  <  0.001), N category 
(HR 3.155, 95% CI 1.855–5.366, P  <  0.001), M category 
(HR 2.275, 95% CI 1.477–3.503, P  <  0.001), and EGFR 
mutation (HR 0.509, 95% CI 0.306–0.848, P  =  0.009). 
The multivariate analysis results showed that histologi-
cal type (HR 1.926, 95% CI 1.102–3.364, P =  0.021), N 
category (HR 2.403, 95% CI 1.166–4.956, P = 0.018), and 
M category (HR 2.164, 95% CI 1.292–3.624, P =  0.003) 
were independent prognostic factors for OS in NSCLC 
(Table  3). According to univariate analysis results, PFS 
were significantly associated with differentiation (HR 
0.744, 95% CI 0.576–0.961, P = 0.023), clinical stage (HR 
1.595, 95% CI 1.202–2.116, P =  0.001), T category (HR 
1.582, 95% CI 1.218–2.055, P =  0.001), N category (HR 
1.438, 95% CI 1.071–1.931, P =  0.016), and M category 
(HR 1.576, 95% CI 1.214–2.046, P = 0.001). Further mul-
tivariate analysis indicated that T category (HR 1.499, 
95% CI 1.144–1.964, P  =  0.003) and M category (HR 
1.477, 95% CI 1.105–1.974, P = 0.008) were independent 
predictors of PFS (Table 3).
Therapeutic responses and clinical outcome of patients 
with ALK rearrangement
Of the 44 patients with ALK rearrangement, 18 (40.9%) 
were treated with crizotinib, 4 (9.1%) were treated with 
an EGFR-TKI, and 22 (50.0%) were treated with conven-
tional chemotherapy. After treated with crizotinib, the 
tumors in the 18 patients shrank, and both the symptoms 
and the quality of life were substantially improved. By the 
last follow-up date, the median OS in the 18 patients with 
ALK rearrangements who were treated with an ALK-TKI 
was higher than that in the 22 patients with ALK rear-
rangements who were treated with conventional chemo-
therapy, but there was no statistical difference (21.2 vs. 
19.1 months, P = 0.587). Because of the short follow-up 
time, no significant difference was found between the 
two groups in terms of OS rate (P = 0.773) or PFS rate 
(P = 0.608).
Discussion
The identification of ALK rearrangements in NSCLC 
is pivotal to guide the appropriate treatment with ALK-
TKI. In this study, we used an ALK break-apart probe 
Table 2 Associations between  EGFR mutation status 
and the clinicopathologic features of patients with NSCLC
All values are presented as number of patients followed by percentages in the 
parentheses. Other footnotes as in Table 1.
Characteristic EGFR mutation [cases (%)] P
Negative Positive
Total 328 (67.4) 159 (32.6)
Age
 ≤58 years 187 (57.0) 74 (46.5) 0.030
 >58 years 141 (43.0) 85 (53.5)
Sex
 Male 231 (70.4) 72 (45.3) <0.001
 Female 97 (29.6) 87 (54.7)
Histological type
 Adenocarcinoma 226 (68.9) 156 (98.1) <0.001
 Others 102 (31.1) 3 (1.9)
Differentiation
 Well 118 (36.0) 88 (55.3) <0.001
 Poor 210 (64.0) 71 (44.7)
Clinical stage
 I + II 153 (46.6) 73 (45.9) 0.879
 III + IV 175 (53.4) 86 (54.1)
Smoking history
 Non‑smoker 130 (39.6) 109 (68.6) <0.001
 Smoker 198 (60.4) 50 (31.4)
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assay to test 487 NSCLC cases and identified 44 (9.0%) 
with ALK rearrangements, which was in accordance 
with the results of previous investigations [25–28]. The 
frequency of ALK rearrangements was 20.3% (25/123) 
in young patients with the adenocarcinoma subtype 
who were non-smokers, which was also consistent with 
the previously reported results [24, 27, 29, 30]. Our 
study also revealed other characteristics of NSCLC with 
ALK rearrangements, such as advanced stage (70.5%, 
31/44) and wild-type EGFR (97.7%, 43/44). Additionally, 
patients with advanced-stage tumors and poorly differen-
tiated tumors had a shorter time to cancer progression in 
comparison with those with early-stage tumors and well 
differentiated tumors.
Fig. 2 Kaplan–Meier overall survival curves stratified by different clinicopathologic parameters in NSCLC patients. a Histological type; b differentia‑
tion; c clinical stage; d smoking history; e epidermal growth factor receptor (EGFR) mutation (MT) status.
Page 7 of 9Fu et al. Chin J Cancer  (2015) 34:35 
Tumors with ALK rearrangement were found to exhibit 
papillary and acinar growth patterns [18], mucinous cri-
briform patterns [17], and a solid signet-ring cell pattern 
[24]. In addition, the coexistence of glandular and squa-
mous morphologies was also reported in previous stud-
ies [18, 24]. In our study, acinar, papillary, and mucinous 
adenocarcinomas were found in ALK-rearranged cases. 
Interestingly, in our study, we also detected ALK rear-
rangements in a case of squamous cell carcinoma. Fur-
thermore, 4 ALK-rearranged adenocarcinomas were 
observed in patients with focal squamous differentiation. 
This suggests that a test for ALK rearrangement should 
be performed in patients with classical morphologic pat-
terns, mixed squamous and adenocarcinoma patterns as 
well as in patients with squamous carcinoma in case of a 
wrong therapeutic decision.
ALK rearrangement was generally reported to be found 
in tumors with wild-type EGFR and KRAS [7, 19, 27, 
31, 32]. However, some investigators also observed the 
coexistence of ALK rearrangement and EGFR mutations 
Fig. 3 Kaplan–Meier progression‑free survival curves stratified by different clinicopathologic parameters in NSCLC patients. a Differentiation; b clini‑
cal stage.
Table 3 Cox regression analysis of OS and PFS in 487 patients with NSCLC
OS overall survival, PFS progression-free survival, HR hazard ratio, CI confidence interval. Other footnotes as in Table 1.
Variable Subset OS PFS
HR (95% CI) P HR (95% CI) P
Univariate analysis
 Age ≤58 vs. >58 1.058 (0.692–1.618) 0.794 0.876 (0.685–1.121) 0.294
 Sex Male vs. female 0.710 (0.448–1.126) 0.146 1.007 (0.781–1.299) 0.958
 Histological type Adenocarcinoma vs. others 1.971 (1.200–3.235) 0.007 1.294 (0.951–1.761) 0.101
 Differentiation Well vs. poor 0.449 (0.279–0.721) 0.001 0.744 (0.576–0.961) 0.023
 Clinical stage I + II vs. III + IV 3.091 (1.855–5.149) <0.001 1.595 (1.202–2.116) 0.001
 Smoking history Non‑smoker vs. smoker 1.779 (1.153–2.747) 0.009 1.100 (0.862–1.403) 0.443
 T category T1–2 vs. T3–4 2.475 (1.605–3.816) <0.001 1.582 (1.218–2.055) 0.001
 N category N0 vs. N1–3 3.155 (1.855–5.366) <0.001 1.438 (1.071–1.931) 0.016
 M category M0 vs. M1 2.275 (1.477–3.503) <0.001 1.576 (1.214–2.046) 0.001
 EGFR mutation Negative vs. positive 0.509 (0.306–0.848) 0.009 0.845 (0.647–1.102) 0.213
 ALK rearrangement Negative vs. positive 1.397 (0.740–2.635) 0.302 1.155 (0.785–1.701) 0.465
Multivariate analysis
 Histological type Adenocarcinoma vs. others 1.926 (1.102–3.364) 0.021 – –
 T category T1–2 vs. T3–4 – – 1.499 (1.144–1.964) 0.003
 N category N0 vs. N1–3 2.403 (1.166–4.956) 0.018 – –
 M category M0 vs. M1 2.164 (1.292–3.624) 0.003 1.477 (1.105–1.974) 0.008
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[33–35]. It was reported that patients who harbor a con-
current EGFR mutation and an ALK rearrangement may 
partially respond to EGFR inhibitors [36–38]. Interest-
ingly, we identified one patient with a concomitant ALK 
rearrangement and EGFR mutation who had undergone 
therapy with erlotinib. Nevertheless, this patient experi-
enced disease progression less than 1 month later as con-
firmed by CT scan. The mechanism of resistance might 
be affected by different signal transduction pathways. 
Sasaki et al. [38] reported that in in vitro studies the co-
expression of an EGFR mutation and the EML4-ALK 
fusion gene might lead to resistance to targeted therapies. 
It is therefore important to determine the optimal combi-
nation of a given EGFR-TKI and ALK inhibitor or other 
new therapeutic regimens for patients with a concomi-
tant EGFR mutation and an ALK rearrangement.
In an analysis of OS and PFS between ALK rearrange-
ment-positive and ALK rearrangement-negative groups, 
no statistical significance was observed. The reason 
might be that the patients with ALK rearrangements, in 
our study, were not treated with targeted therapy or they 
were treated for only a short time. Li et al. [39] reported 
that EGFR/KRAS mutation status appeared to be sig-
nificantly associated with neither PFS nor OS if these 
patients did not receive targeted therapies. This hypoth-
esis is consistent with the results of our study. All evi-
dence supports the hypothesis that gene subtypes could 
only predict the therapeutic response but not the survival 
benefit until patients received a given molecular targeted 
therapy.
Patients with EGFR mutations demonstrated a supe-
rior PFS after treatment with molecular targeted therapy 
compared with those treated with traditional platinum-
doublet chemotherapy [40]. However, in our study, dis-
ease progression was observed in two patients with ALK 
rearrangement after they were treated with crizotinib, 
and the two patients were considered resistant to cri-
zotinib. Presently, the mechanism of resistance to ALK 
inhibitors is thought to be a compensatory mechanism 
or the occurrence of drug-resistant gene mutation, such 
as a mutation in ALK, EGFR, KRAS, or BRAF [41, 42]. 
Rapid disease progression can deprive the patients of a 
second chance for survival. Spaans et al. [42] suggested 
that a combination targeted therapy that simultaneously 
inhibits multiple resistance pathways would elicit a better 
clinical response. However, the toxicity of combination 
drugs requires further investigation.
There are some limitations in our study. First, this 
was a retrospective study and all cases were selected 
within a single hospital. Second, many patients with 
ALK rearrangement or EGFR mutations could not 
receive targeted therapy or they had a short medica-
tion duration due to budget limitations. Therefore, we 
were not able to exclude geographic and demographic 
variations that might have influenced the outcome of 
the study.
In conclusion, the patients who harbor ALK rear-
rangements tend to be relatively young, non-smokers or 
light smokers with the adenocarcinoma subtype. Prior 
to treatment, it is necessary to assess ALK rearrange-
ment status to determine the appropriate therapeutic 
regimen. Because the underlying mechanism of the par-
tial response to targeted therapy is unknown, we will 
continue to investigate this mechanism in patients with 
NSCLC in the future.
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